# Aleniglipron · PepVault guides

Source: https://pepvault.app/guides/aleniglipron-switch-trial

Last updated: 2026-11-20

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Guides](https://pepvault.app/guides) [GLP-1s](https://pepvault.app/guides#glp1)

# Aleniglipron: the GLP-1 pill, and the trial switching people from shots to it

Reviewed November 2026 14 sources [Published by PepVault](https://pepvault.app/guides/how-we-research)

Aleniglipron is Structure Therapeutics' daily GLP-1 pill in testing: its phase 2 numbers, every trial, and what its shot-to-pill SWITCH trial must beat.

- **Last reviewed:** Nov 20, 2026
- **Sources:** 14
- **Questions:** 8
- **Compounds:** 3

## The short answer

Aleniglipron is Structure Therapeutics' once-daily GLP-1 pill, still in trials and approved nowhere. In phase 2, weight fell up to 16.3% more than on placebo at 44 weeks. Its SWITCH trial moves people from a GLP-1 shot to the pill for 12 weeks; Structure expects the data in Q4 2026. The bar: orforglipron kept 75 to 79% of the shot's loss for a year in people whose weight had plateaued.

Every number checked at its primary source · Nov 20, 2026 · [14 sources](https://pepvault.app/guides/aleniglipron-switch-trial#sources) · [How we research](https://pepvault.app/guides/how-we-research)

**Evidence:** Early for aleniglipron: company-run phase 2 trials in people (ACCESS, 230 people, published; ACCESS II, 85 people, and a 72-week open-label extension, company releases), phase 3 enrolling, SWITCH not yet reported. The bar comes from large phase 3 trials of other drugs.

## What is aleniglipron?

Aleniglipron is an experimental weight-loss pill taken once a day, made by Structure Therapeutics of San Francisco[1](https://pepvault.app/guides/aleniglipron-switch-trial#source-1). Its code name is **GSBR-1290**, and the trials are registered under **Gasherbrum Bio**, which the registry lists as a wholly owned subsidiary of Structure, so the two names are the same program[14](https://pepvault.app/guides/aleniglipron-switch-trial#source-14).

It belongs to the same class as Wegovy and Zepbound: a GLP-1 receptor agonist, a drug that switches on the body's receptor for GLP-1, the gut hormone that helps set appetite. The difference is the molecule. Semaglutide and tirzepatide are peptides, chains of amino acids that the stomach breaks down, which is why they are injected or, for the Wegovy pill, need strict fasting rules. Aleniglipron is a small molecule, a compact chemical built to survive the gut and be absorbed as a pill[4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4). It is in the same family as Lilly's orforglipron, which the FDA approved as Foundayo in April 2026.

As of November 20, 2026, aleniglipron is approved nowhere and is available only inside clinical trials. Its phase 3 program, the large trials a drug needs before approval, opened its first sites in July 2026, per the registry; Structure dates the start to August[1](https://pepvault.app/guides/aleniglipron-switch-trial#source-1) [9](https://pepvault.app/guides/aleniglipron-switch-trial#source-9) [10](https://pepvault.app/guides/aleniglipron-switch-trial#source-10).

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

After a switch, the weight is the result that counts. PepVault's weight log draws your trend week by week, so a slow drift up shows early, while there is still time to talk it over with your prescriber.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## How does aleniglipron work?

It does what the GLP-1 shots do, from a pill: it acts like GLP-1, the hormone that lowers appetite, makes a meal feel filling sooner and slows how fast the stomach empties[4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4). Structure shaped the molecule to fit the receptor's own structure and describes it as selective and biased: it acts on the GLP-1 receptor alone and favours some of the receptor's signals over others[4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4).

In the trials it is swallowed once a day and stepped up every four weeks to a target dose, the same slow climb the shots use to let the stomach adjust[4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4). The phase 3 trials start at 2.5 mg and climb to 45, 90 or 180 mg a day[1](https://pepvault.app/guides/aleniglipron-switch-trial#source-1).

## How much weight did people lose on aleniglipron?

Between 8% and 16% of body weight beyond placebo, rising with the dose. ACCESS, the main phase 2b trial, gave 230 adults 45, 90 or 120 mg a day or a placebo pill for 36 weeks; on 120 mg, weight fell 12.1% against 0.8% on placebo, and 70% of people lost at least 10%[4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4). ACCESS II tested higher doses in 85 people for 44 weeks[3](https://pepvault.app/guides/aleniglipron-switch-trial#source-3).

| Trial | People | Weeks | Top dose | Weight change on the drug | Beyond placebo |
| --- | --- | --- | --- | --- | --- |
| ACCESS (phase 2b)[4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4) | 230 | 36 | 120 mg | -12.1% | -11.3% |
| ACCESS II (phase 2)[3](https://pepvault.app/guides/aleniglipron-switch-trial#source-3) | 85 | 44 | 180 mg | -15.3% | -16.3% |
| ACCESS II (phase 2)[3](https://pepvault.app/guides/aleniglipron-switch-trial#source-3) | 85 | 44 | 240 mg | -15.0% | -16.0% |
| ACCESS open-label extension[2](https://pepvault.app/guides/aleniglipron-switch-trial#source-2) | ACCESS completers | 72 | up to 180 mg | -16.2% (from the 120 mg arm) | no placebo group |

The weight was still falling at the end of each trial: Structure reports no plateau at 36, 44 or 72 weeks in the top dose groups[2](https://pepvault.app/guides/aleniglipron-switch-trial#source-2) [3](https://pepvault.app/guides/aleniglipron-switch-trial#source-3) [4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4). In the extension, more than a third of people in the two highest groups lost over 20% of their weight by week 72[2](https://pepvault.app/guides/aleniglipron-switch-trial#source-2). These are small phase 2 trials and the extension has no placebo group (it is open-label: everyone knows they take the drug), so the phase 3 trials will give the firm numbers.

## With this guide

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Open-label](https://pepvault.app/glossary/open-label)
- [Primary endpoint](https://pepvault.app/glossary/primary-endpoint)

## What side effects came with aleniglipron in the trials?

The usual GLP-1 ones, in the stomach and gut, mostly mild to moderate and mostly early. In ACCESS, nausea was reported by 65% of people on 120 mg against 21% on placebo, and vomiting by 32% against 5%[4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4). They eased over time, and vomiting rarely came back after a paused dose was restarted[4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4).

The start mattered. With a 5 mg first step, 10.4% of people on aleniglipron in ACCESS stopped because of side effects[4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4). Fewer than 5% stopped across the 72-week extension, and the placebo group that started there at 2.5 mg had fewer stomach side effects than the 5 mg start in ACCESS[2](https://pepvault.app/guides/aleniglipron-switch-trial#source-2). The phase 3 trials now use the 2.5 mg start[1](https://pepvault.app/guides/aleniglipron-switch-trial#source-1). ACCESS found no drug-caused liver injury, and the liver enzyme rises that did occur went back to normal without stopping the drug[4](https://pepvault.app/guides/aleniglipron-switch-trial#source-4).

## What is the aleniglipron SWITCH trial testing?

Whether people who already lost weight on an approved GLP-1 injection can move to the aleniglipron pill and keep the weight off[1](https://pepvault.app/guides/aleniglipron-switch-trial#source-1). Structure describes it as testing the move from an injectable GLP-1 receptor agonist to once-daily aleniglipron for weight-loss maintenance, comparing different aleniglipron starting doses over 12 weeks[1](https://pepvault.app/guides/aleniglipron-switch-trial#source-1). Structure calls it a phase 1 study[2](https://pepvault.app/guides/aleniglipron-switch-trial#source-2).

The starting dose is the practical question. Someone coming off a full-dose shot is already used to a GLP-1, so climbing from 2.5 mg again would leave weeks on a weak dose. Lilly asked the same question with orforglipron and moved people straight to 12 mg (9 mg in today's tablets), skipping the first steps: about one in ten (10.5% and 9.5% in the two groups) had nausea, vomiting or diarrhea in the first four weeks, mostly mild to moderate, and none needed a lower dose[11](https://pepvault.app/guides/aleniglipron-switch-trial#source-11).

Structure has not published how many people are in SWITCH, which shots they came from, or the doses tested, and we found no SWITCH record on ClinicalTrials.gov: none of the 11 aleniglipron records there is a switch study[14](https://pepvault.app/guides/aleniglipron-switch-trial#source-14). This page fills those in when Structure reports.

## What would count as a good SWITCH result?

Weight that holds steady for the 12 weeks. The comparison is what happens when the shot simply stops: in the withdrawal trials, weight came back within months. The one switch trial with results, orforglipron's ATTAIN-MAINTAIN, sets the bar for a pill[11](https://pepvault.app/guides/aleniglipron-switch-trial#source-11).

| Trial | What happened after the shot | Weeks | Result |
| --- | --- | --- | --- |
| SURMOUNT-4[12](https://pepvault.app/guides/aleniglipron-switch-trial#source-12) | Tirzepatide stopped (placebo) | 52 | Weight up 14.0% (kept on tirzepatide: down a further 5.5%) |
| STEP 1 extension[13](https://pepvault.app/guides/aleniglipron-switch-trial#source-13) | Semaglutide stopped, no treatment | 52 | Regained 11.6 of the 17.3 points lost, about two-thirds |
| ATTAIN-MAINTAIN, from tirzepatide[11](https://pepvault.app/guides/aleniglipron-switch-trial#source-11) | Orforglipron pill vs placebo pill | 52 | Kept 74.7% of the loss on the pill vs 49.2% on placebo (people whose weight had plateaued) |
| ATTAIN-MAINTAIN, from semaglutide[11](https://pepvault.app/guides/aleniglipron-switch-trial#source-11) | Orforglipron pill vs placebo pill | 52 | Kept 79.3% of the loss on the pill vs 37.6% on placebo (people whose weight had plateaued) |

ATTAIN-MAINTAIN's early weeks are the closest match to SWITCH's 12. Among people who stayed on the pill, those coming off tirzepatide were 21.5% below their original weight at the switch and 19.0% below it at week 24; those coming off semaglutide went from 16.5% to 16.3%, keeping almost all of it[11](https://pepvault.app/guides/aleniglipron-switch-trial#source-11). So a strong SWITCH result keeps weight within a point or two of where the shot left it, and a starting dose that skips the slow climb without a wave of nausea.

The number to watch beside the weight is how many people stop the pill because of side effects. In ATTAIN-MAINTAIN that was 4.8% to 7.3%[11](https://pepvault.app/guides/aleniglipron-switch-trial#source-11); aleniglipron's 72-week extension came in under 5%[2](https://pepvault.app/guides/aleniglipron-switch-trial#source-2). A 12-week trial is short, so even a clean result shows the first step of a switch, not a year of maintenance.

<!--promo-->

After a switch, the weight is the result that counts. PepVault's weight log draws your trend week by week, so a slow drift up shows early, while there is still time to talk it over with your prescriber. [Track your weight in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-aleniglipron-switch-trial-inline&mt=8)

<!--/promo-->

## Which aleniglipron trials are in the registry?

Eleven, all sponsored by Gasherbrum Bio, as of November 20, 2026[14](https://pepvault.app/guides/aleniglipron-switch-trial#source-14). Dates are primary completion, per ClinicalTrials.gov: when the main measurement ends, not when results are released. "Est." marks the sponsor's estimate; the rest are actual dates.

| Trial | Phase | People | Primary completion | Status |
| --- | --- | --- | --- | --- |
| NCT05762471, adults with overweight or obesity, and with type 2 diabetes | 1b/2a | 142 | Apr 2024 | Completed |
| NCT05893043, Japanese and non-Japanese healthy adults | 1 | 18 | Jun 2023 | Completed |
| NCT06139055, healthy adults with overweight or obesity | 1 | 70 | Mar 2024 (est.) | Unknown |
| NCT06693843, ACCESS[5](https://pepvault.app/guides/aleniglipron-switch-trial#source-5) | 2b | 230 | Oct 2025 | Completed |
| NCT06703021, ACCESS II[6](https://pepvault.app/guides/aleniglipron-switch-trial#source-6) | 2 | 85 | Jan 2026 | Completed |
| NCT07169942, body composition[7](https://pepvault.app/guides/aleniglipron-switch-trial#source-7) | 2 | 71 | Sep 2026 | Completed |
| NCT07400588, type 2 diabetes[8](https://pepvault.app/guides/aleniglipron-switch-trial#source-8) | 2 | 58 | Sep 2026 | Completed |
| NCT07654361, ACCOMPLISH-1[9](https://pepvault.app/guides/aleniglipron-switch-trial#source-9) | 3 | 3,600 (planned) | Sep 2028 (est.) | Recruiting |
| NCT07654374, ACCOMPLISH-2, with type 2 diabetes[10](https://pepvault.app/guides/aleniglipron-switch-trial#source-10) | 3 | 1,100 (planned) | Sep 2028 (est.) | Recruiting |
| NCT07872033, liver impairment | 1 | 36 (planned) | Aug 2027 (est.) | Recruiting |
| NCT07946068, kidney impairment | 1 | 16 (planned) | Mar 2027 (est.) | Not yet recruiting |

The two ACCOMPLISH trials are the ones that could lead to approval. Both compare 45, 90 or 180 mg a day with placebo, and their primary endpoint, the main measure each trial is built to answer, is the change in body weight at week 76[9](https://pepvault.app/guides/aleniglipron-switch-trial#source-9) [10](https://pepvault.app/guides/aleniglipron-switch-trial#source-10).

## When will aleniglipron's next results come out?

Structure expects three readouts in the fourth quarter of 2026: SWITCH, the 44-week body composition trial (how much of the weight lost is fat) and the 30-week type 2 diabetes trial[1](https://pepvault.app/guides/aleniglipron-switch-trial#source-1). The body composition and diabetes trials have finished their main measurements, per ClinicalTrials.gov[7](https://pepvault.app/guides/aleniglipron-switch-trial#source-7) [8](https://pepvault.app/guides/aleniglipron-switch-trial#source-8). Structure expects topline phase 3 results in the second half of 2028[1](https://pepvault.app/guides/aleniglipron-switch-trial#source-1).

**Has SWITCH reported yet?** Not as of November 20, 2026. Structure's latest update, on November 9, still lists it as expected in Q4 2026, and its two posters at ObesityWeek (November 14 to 17), scheduled for November 15, covered the extension and the dose-ranging results across the ACCESS trials, not SWITCH[1](https://pepvault.app/guides/aleniglipron-switch-trial#source-1). This page is updated when the result lands.

Until then, the one pill with switch data is orforglipron, sold as Foundayo. Moving between GLP-1 medicines, and the dose to start on, is a plan made with the prescriber.

<!--promo-->

Moving from a weekly shot to a daily pill? In PepVault you finish the shot's plan and start the pill's, so both stay in one history beside your weight. [Log it in PepVault](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-aleniglipron-switch-trial-inline&mt=8)

<!--/promo-->

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-next&mt=8)

<!--/promo-->

## Sources

1. Structure Therapeutics. Third quarter 2026 financial results and recent highlights (Form 8-K, Exhibit 99.1). November 9, 2026. [sec.gov](https://www.sec.gov/Archives/edgar/data/1888886/000110465926124494/tm2629207d1_ex99-1.htm)
2. Structure Therapeutics. Positive clinical data across oral small molecule amylin and GLP-1 programs: ACCESS open-label extension, 72 weeks (Form 8-K, Exhibit 99.1). September 8, 2026. [sec.gov](https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_ex99-1.htm)
3. Structure Therapeutics. Positive topline data from phase 2 ACCESS II trial of aleniglipron, 44 weeks (Form 8-K, Exhibit 99.1). March 16, 2026. [sec.gov](https://www.sec.gov/Archives/edgar/data/1888886/000110465926028023/tm268880d1_ex99-1.htm)
4. Rosenstock J et al. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2026;32(8):2941-2947. [PubMed 42249138](https://pubmed.ncbi.nlm.nih.gov/42249138/)
5. ClinicalTrials.gov. NCT06693843: ACCESS, a phase 2b dose-range finding study of aleniglipron (GSBR-1290). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06693843)
6. ClinicalTrials.gov. NCT06703021: ACCESS II, a dose-range study of aleniglipron (GSBR-1290). [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06703021)
7. ClinicalTrials.gov. NCT07169942: aleniglipron phase 2 body composition study. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07169942)
8. ClinicalTrials.gov. NCT07400588: aleniglipron phase 2 in type 2 diabetes mellitus. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07400588)
9. ClinicalTrials.gov. NCT07654361: ACCOMPLISH-1, aleniglipron in obesity or overweight with a weight-related comorbidity. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654361)
10. ClinicalTrials.gov. NCT07654374: ACCOMPLISH-2, aleniglipron in obesity or overweight with type 2 diabetes. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654374)
11. Aronne LJ et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32(7):2679-2687. [PubMed 42120723](https://pubmed.ncbi.nlm.nih.gov/42120723/)
12. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. [PubMed 38078870](https://pubmed.ncbi.nlm.nih.gov/38078870/)
13. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. [PubMed 35441470](https://pubmed.ncbi.nlm.nih.gov/35441470/)
14. ClinicalTrials.gov. All studies with lead sponsor Gasherbrum Bio, Inc. (a wholly owned subsidiary of Structure Therapeutics), read November 20, 2026. [clinicaltrials.gov](https://clinicaltrials.gov/search?spons=Gasherbrum%20Bio)

<!--promo-->

Newsletter · Weekly

## The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

<!--/promo-->

## Next guide · GLP-1

Guide · GLP-1

### [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)

Mounjaro and Zepbound side effects at 5, 10 and 15 mg against placebo, from the labels' trial tables: when they show up, how many stopped, and what helps.

Read the next guide

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## In the library

- [Orforglipron Studied range: 0.8–17.2 mg](https://pepvault.app/peptides/orforglipron)
- [Tirzepatide Studied range: 2.5–15 mg](https://pepvault.app/peptides/tirzepatide)
- [Semaglutide Studied range: 0.25–2.4 mg](https://pepvault.app/peptides/semaglutide)

## Related guides

- Guide · GLP-1s

  ### [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)

  Foundayo (orforglipron) is a daily GLP-1 pill, not a peptide. Its ATTAIN and ACHIEVE results beside Zepbound's SURMOUNT and Wegovy's STEP, in one table.

  Read the guide
- Guide · GLP-1s

  ### [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)

  What happened to weight when semaglutide and tirzepatide were stopped in STEP 1, STEP 4 and SURMOUNT-4: how much came back, how fast, and what the labels say.

  Read the guide
- Guide · GLP-1s

  ### [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)

  The Wegovy pill is daily semaglutide, FDA approved in December 2025. How to take it, its doses beside the weekly shot's, and OASIS 4 next to STEP 1.

  Read the guide

## Guides

- [All guides](https://pepvault.app/guides)
- [How we research](https://pepvault.app/guides/how-we-research)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this guide

### Orforglipron

- [Orforglipron: the full reference](https://pepvault.app/peptides/orforglipron)
- [Orforglipron dose guide](https://pepvault.app/lab/dosage/orforglipron)

### Tirzepatide

- [Tirzepatide: the full reference](https://pepvault.app/peptides/tirzepatide)
- [Tirzepatide dose guide](https://pepvault.app/lab/dosage/tirzepatide)

### Mixing charts

- [Tirzepatide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-5mg)
- [Tirzepatide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-10mg)
- [Tirzepatide 15 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-15mg)
- [Tirzepatide 30 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-30mg)
- [Tirzepatide 60 mg vial](https://pepvault.app/tools/reconstitution-calculator/tirzepatide-60mg)
- [Semaglutide 2 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-2mg)
- [Semaglutide 5 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-5mg)
- [Semaglutide 10 mg vial](https://pepvault.app/tools/reconstitution-calculator/semaglutide-10mg)

### Studies

- [Orforglipron: heart events no worse than insulin in ACHIEVE-4](https://pepvault.app/research/orforglipron-achieve-4-2026)
- [Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2](https://pepvault.app/research/orforglipron-attain-2-2026)
- [Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3](https://pepvault.app/research/semaglutide-achieve-3-2026)
- [All 5 studies](https://pepvault.app/research#orforglipron)
- [Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZE](https://pepvault.app/research/tirzepatide-embraze-2026)
- [Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks](https://pepvault.app/research/tirzepatide-surmount-maintain-2026)
- [Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c](https://pepvault.app/research/dulaglutide-surpass-switch-2025)
- [All 19 studies](https://pepvault.app/research#tirzepatide)

### Compared with

- [Orforglipron vs Semaglutide](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide)
- [Orforglipron vs Tirzepatide](https://pepvault.app/peptides/compare/orforglipron-vs-tirzepatide)
- [Orforglipron vs Semaglutide (oral)](https://pepvault.app/peptides/compare/orforglipron-vs-semaglutide-oral)
- [Retatrutide vs Orforglipron](https://pepvault.app/peptides/compare/retatrutide-vs-orforglipron)
- [Retatrutide vs Tirzepatide](https://pepvault.app/peptides/compare/retatrutide-vs-tirzepatide)
- [Semaglutide vs Tirzepatide](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)
- [GLP-1 titration planner](https://pepvault.app/tools/glp1-titration-calculator)
- [GLP-1 weight loss by week](https://pepvault.app/tools/glp1-weight-loss-by-week)

### The GLP-1 path

- [Retatrutide week by week](https://pepvault.app/guides/retatrutide-week-by-week)
- [Retatrutide dosage: the trial step-ups](https://pepvault.app/guides/retatrutide-dosage-in-trials)
- [Tirzepatide week by week](https://pepvault.app/guides/tirzepatide-week-by-week)
- [Semaglutide week by week](https://pepvault.app/guides/semaglutide-week-by-week)
- [Tirzepatide dosage: every step from 2.5 to 15 mg (Mounjaro and Zepbound)](https://pepvault.app/guides/tirzepatide-dosage)
- [Wegovy and Ozempic dosage: both labels' steps in one table, and why the two differ](https://pepvault.app/guides/wegovy-and-ozempic-dosage)
- [How to use the Zepbound KwikPen](https://pepvault.app/guides/how-to-use-the-zepbound-kwikpen)
- [How to use the Ozempic and Wegovy pens: needles, the dose counter and clicks](https://pepvault.app/guides/how-to-use-ozempic-and-wegovy-pens)
- [What time of day to take your GLP-1 shot or pill, and can you change the day?](https://pepvault.app/guides/when-to-take-your-glp-1)
- [Switching GLP-1s: Ozempic to Zepbound, shot to pill, and what the trials tested](https://pepvault.app/guides/switching-between-glp-1s)
- [Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table](https://pepvault.app/guides/ozempic-wegovy-mounjaro-zepbound)
- [Is Ozempic insulin? GLP-1, GIP and insulin explained](https://pepvault.app/guides/is-ozempic-insulin)
- [The Wegovy pill: what it is, how its label differs from the shot, and the trial numbers](https://pepvault.app/guides/the-wegovy-pill)
- [Ozempic and Wegovy side effects: what the trials counted and when they showed up](https://pepvault.app/guides/ozempic-and-wegovy-side-effects)
- [Semaglutide vs tirzepatide side effects: what the head-to-head trials found](https://pepvault.app/guides/sema-vs-tirzepatide-side-effects)
- [Microdosing a GLP-1: what it means and what has been tested](https://pepvault.app/guides/microdosing-a-glp-1)
- [GLP-1s and sleep apnea: Zepbound's OSA approval](https://pepvault.app/guides/glp-1-and-sleep-apnea)
- [Retatrutide first dose: the first four weeks in the trials](https://pepvault.app/guides/retatrutide-first-dose)
- [Retatrutide side effects: what the trials counted](https://pepvault.app/guides/retatrutide-side-effects)
- [Retatrutide not working? Stalls, slow responders and the plateau](https://pepvault.app/guides/retatrutide-not-working)
- [Switching from tirzepatide to retatrutide: what is known](https://pepvault.app/guides/tirzepatide-to-retatrutide)
- [Is retatrutide safe? What the trials reported](https://pepvault.app/guides/is-retatrutide-safe)
- [When will retatrutide be approved?](https://pepvault.app/guides/when-will-retatrutide-be-approved)
- [TRIUMPH-5 results: retatrutide vs tirzepatide head to head](https://pepvault.app/guides/triumph-5-results)
- [CagriSema FDA approval: when it's due, the dose filed, and what the trials showed](https://pepvault.app/guides/cagrisema-fda-decision)
- [MariTide phase 3 results (MARITIME-1): what to expect](https://pepvault.app/guides/maritime-1-results)
- [Mounjaro and Zepbound side effects by dose: the rates at each step](https://pepvault.app/guides/mounjaro-zepbound-side-effects)
- [Hair loss on a GLP-1: how common it is per drug, and why](https://pepvault.app/guides/hair-loss-on-a-glp-1)
- ["Ozempic face": what it is, and where the weight comes from](https://pepvault.app/guides/ozempic-face)
- [Foundayo (orforglipron) vs the shots: the trial numbers side by side](https://pepvault.app/guides/foundayo-vs-the-shots)
- [Is compounded semaglutide or tirzepatide the same as Ozempic or Zepbound?](https://pepvault.app/guides/compounded-glp-1-vs-brand)
- [Why compounded semaglutide and tirzepatide come with B12, glycine or B6, and what it changes](https://pepvault.app/guides/compounded-glp-1-with-b12)
- [Is there a generic Ozempic? Generic semaglutide and Sevmia](https://pepvault.app/guides/generic-semaglutide)
- [How much does a GLP-1 cost in 2026? Zepbound, Wegovy and Medicare prices](https://pepvault.app/guides/how-much-does-a-glp-1-cost)
- [What to eat on a GLP-1: what the trials and the guidelines say](https://pepvault.app/guides/what-to-eat-on-a-glp-1)
- [How much protein per day? The numbers by weight and goal](https://pepvault.app/guides/how-much-protein-per-day)
- [Muscle on a GLP-1: how much of the weight lost is lean mass?](https://pepvault.app/guides/muscle-on-a-glp-1)
- [Intermittent fasting on a GLP-1: what the trials and labels say](https://pepvault.app/guides/intermittent-fasting-on-a-glp-1)
- [Coffee on a GLP-1: can you drink it, and why it can taste different](https://pepvault.app/guides/coffee-on-a-glp-1)
- [Food noise on a GLP-1: what it is and what happens after stopping](https://pepvault.app/guides/food-noise-on-a-glp-1)
- [GLP-1s and menopause: what the trials say about women in midlife](https://pepvault.app/guides/glp-1s-and-menopause)
- [Stopping a GLP-1: what happens to your weight](https://pepvault.app/guides/stopping-a-glp-1)
- [How to keep the weight off after a GLP-1: what each trial tested](https://pepvault.app/guides/keeping-weight-off-after-a-glp-1)
- [Berberine vs metformin vs a GLP-1: what each does to weight and glucose](https://pepvault.app/guides/berberine-vs-metformin-vs-glp-1)
- [Natural GLP-1 alternatives: what the evidence shows for berberine, fiber and supplements](https://pepvault.app/guides/natural-glp-1-alternatives)
- [What is 5-Amino-1MQ? What's been measured](https://pepvault.app/guides/5-amino-1mq-explained)
- [Retatrutide from a lab vial: what independent testing found](https://pepvault.app/guides/retatrutide-lab-vial-tests)
- [Switching from Saxenda to Wegovy: how the change works](https://pepvault.app/guides/saxenda-to-wegovy)
- [Do you stop Ozempic, Wegovy, Mounjaro or Zepbound before surgery?](https://pepvault.app/guides/glp-1-before-surgery)
- [Diarrhea on a GLP-1: how common, and how long it lasts](https://pepvault.app/guides/diarrhea-on-a-glp-1)
- [Dizziness on a GLP-1: dehydration, blood pressure or blood sugar?](https://pepvault.app/guides/dizziness-on-a-glp-1)
- [Heartburn and acid reflux on a GLP-1: the rates, the timing and what helps](https://pepvault.app/guides/heartburn-on-a-glp-1)
- [Does Ozempic or Mounjaro make you tired? Fatigue in the trials](https://pepvault.app/guides/glp-1-fatigue)
- [Can a GLP-1 cause low blood sugar if you do not have diabetes?](https://pepvault.app/guides/glp-1-low-blood-sugar)
- [Is there a medicine for GLP-1 nausea? Tradipitant, so far](https://pepvault.app/guides/tradipitant-for-glp-1-nausea)
- [GLP-1s and mood: depression, anxiety and what the FDA review found](https://pepvault.app/guides/glp-1s-and-mood)
- [Can Ozempic cause vision loss? GLP-1s and NAION, by the numbers](https://pepvault.app/guides/glp-1-and-naion)
- [Are GLP-1s safe long term? What the longest trials show](https://pepvault.app/guides/are-glp-1s-safe-long-term)
- [GLP-1s and the kidneys: what FLOW showed, and the dehydration risk](https://pepvault.app/guides/glp-1s-and-the-kidneys)
- [Can you drink alcohol on Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/alcohol-on-a-glp-1)
- [Do GLP-1s reduce alcohol cravings? What the trials found](https://pepvault.app/guides/glp-1-and-alcohol-cravings)
- [GLP-1s and fatty liver: what the trials measured](https://pepvault.app/guides/glp-1-and-fatty-liver)
- [GLP-1s after a gastric sleeve or bypass: regain, dosing and sleeve vs GLP-1](https://pepvault.app/guides/glp-1-after-bariatric-surgery)
- [Can you drink alcohol on retatrutide?](https://pepvault.app/guides/retatrutide-and-alcohol)
- [Ozempic, Wegovy, Mounjaro or Zepbound not working? Slow responders and plateaus in the trials](https://pepvault.app/guides/glp-1-not-working)
- [Intermittent fasting for weight and fat loss: what the trials measured](https://pepvault.app/guides/intermittent-fasting-weight-loss)
- [Can you take metformin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/metformin-with-a-glp-1)
- [GLP-1s and pregnancy: Ozempic, Wegovy, Mounjaro and Zepbound before and during](https://pepvault.app/guides/glp-1s-and-pregnancy)
- [Can you take Ozempic, Mounjaro or another GLP-1 while breastfeeding?](https://pepvault.app/guides/glp-1-while-breastfeeding)
- [Eloralintide, petrelintide and amycretin: the amylin drugs in trials](https://pepvault.app/guides/amylin-drugs-in-trials)
- [Olatorepatide (HS-20094): Regeneron's obesity drug, what is known so far](https://pepvault.app/guides/olatorepatide-explained)
- [Cagrilintide and CagriSema: what amylin adds to semaglutide](https://pepvault.app/guides/cagrilintide-and-cagrisema)
- [Berobenatide (PF-08653944, MET-097i): Pfizer's monthly GLP-1 shot, what is known so far](https://pepvault.app/guides/berobenatide-explained)
- [The GLP-1 pipeline: every drug in phase 2 and 3, and when its trials finish](https://pepvault.app/guides/glp-1-pipeline)
- [Is there a monthly GLP-1 shot? MariTide and berobenatide](https://pepvault.app/guides/monthly-glp-1-shots)
- [Cagrilintide alone: RENEW 1 phase 3 results and what to expect](https://pepvault.app/guides/renew-1-cagrilintide-results)
- [Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg](https://pepvault.app/guides/wegovy-hd-7-2-mg)
- [Zenagamtide (amycretin): Novo's GLP-1 and amylin shot and pill, what the trials show](https://pepvault.app/guides/zenagamtide-amycretin)
- [Wegovy and Ozempic price, Medicare and WADA: what changes on January 1, 2027](https://pepvault.app/guides/glp-1-changes-january-2027)
- [Can you take sermorelin with Ozempic, Mounjaro or another GLP-1?](https://pepvault.app/guides/sermorelin-with-a-glp-1)
- [Retatrutide in women: what the studies included](https://pepvault.app/guides/retatrutide-in-women)
- [Peptides for women: what the trials in women show, and after 40](https://pepvault.app/guides/peptides-for-women)
- [Low-dose naltrexone (LDN) for weight loss: what the trials measured](https://pepvault.app/guides/ldn-for-weight-loss)
- [GLP-1s and PCOS: what the trials show, and how they compare with metformin](https://pepvault.app/guides/glp-1-and-pcos)
- [GLP-1s and sleep: insomnia, vivid dreams and the sleep apnea approval](https://pepvault.app/guides/glp-1s-and-sleep)

### Terms on this page

- [Peptide](https://pepvault.app/glossary/peptide)
- [Amino acid](https://pepvault.app/glossary/amino-acid)
- [Receptor agonist](https://pepvault.app/glossary/receptor-agonist)
- [GLP-1](https://pepvault.app/glossary/glp-1)
- [Placebo](https://pepvault.app/glossary/placebo)
- [Open-label](https://pepvault.app/glossary/open-label)
- [Primary endpoint](https://pepvault.app/glossary/primary-endpoint)

<!--promo-->

PepVault for iPhone

## Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?ppid=616838ec-3248-400f-bd58-4b93f85f1a20&pt=129020030&ct=guide-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
